Overview

Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus

Status:
Terminated
Trial end date:
2017-06-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of brentuximab vedotin in adults with active systemic lupus erythematosus (SLE).
Phase:
Phase 2
Details
Lead Sponsor:
Seagen Inc.
Seattle Genetics, Inc.
Treatments:
Antibodies, Monoclonal
Brentuximab Vedotin